{"url_path":"/sec/lfwd/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-20","source_url":"https://www.sec.gov/Archives/edgar/data/1607962/0001178913-26-002862-index.html","accession_number":"0001178913-26-002862","cik":"0001607962","ticker":"LFWD","issuer_name":"Lifeward Ltd.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1607962/0001178913-26-002862-index.html","primary_entity_key":"0001607962","primary_entity_name":"Lifeward Ltd."},"word_count":2808,"has_tables":true,"body_markdown":"Lifeward Ltd. - 1607962 - 2026\n\nDuring the three months ended March 31, 2026, $443 thousand of the December 31, 2025 deferred revenues balance was recognized as revenues.\nIncludes net financing expense comprised of interest expense and changes in fair value of warrant and derivative liabilities related to Oramed Pharmaceuticals Inc., a related party, of $416 for the three months ended March 31, 2026.\nBalance relates entirely to a related party arrangement with Oramed Pharmaceuticals Inc.\n0001607962Q1false00-0000000--12-31See Note 8f to the condensed consolidated financial statements.\nRepresents cash acquired in connection with the acquisition of Oratech from Oramed Pharmaceuticals Inc., a related party, of $6,500.\nSee Note 9 to the condensed consolidated financial statements.\nRepresents proceeds from issuance of Additional Notes to Oramed Pharmaceuticals Inc., a related party, of $1,025 for the three months ended March 31, 2026.\nIncludes proceeds from issuance of New Notes, derivative liabilities and warrant liabilities to Oramed Pharmaceuticals Inc., a related party, of $4,397 for the three months.\nReflects the one-for-twelve reverse share split that became effective on February 24, 2026. See Note 8a to the condensed consolidated financial statements.\nSee Note 6 to the condensed consolidated financial statements.\nCalculation of weighted average remaining contractual term does not include the RSUs that were granted, which have an indefinite contractual term.\nRepresents warrants that were issued to certain institutional purchasers in a private placement in the Company’s private placement offering of ordinary shares in December 2020. As of March 31, 2026, 42,834 warrants were exercised for a total consideration of $4,821,416. During the three months that ended March 31, 2026, no warrants were exercised.\nRepresents warrants that were issued to the placement agent as compensation for its role in the Company’s December 2020 private placement. As of March 31, 2026, 2,690 warrants were exercised for a total consideration of $405,003. During the three months that ended March 31, 2026, no warrants were exercised.\nRepresents warrants that were issued to certain institutional purchasers in a private placement in the Company’s private placement offering of ordinary shares in February 2021.\nRepresents warrants that were issued to the placement agent as compensation for its role in the Company’s February 2021 private placement.\nRepresents warrants that were issued to certain institutional purchasers in a private placement in the Company’s registered direct offering of ordinary shares in September 2021.\nRepresents warrants that were issued to the placement agent as compensation for its role in the Company’s September 2021 registered direct offering.\nRepresents warrants that were issued to certain institutional purchasers in a private placement in the Company’s registered direct offering of ordinary shares in January 2025.\nRepresents warrants that were issued to the placement agent as compensation for its role in the Company’s January 2025 registered direct offering.\nRepresents warrants that were issued to certain institutional investors in connection with the Company’s public offering of ordinary shares in June 2025.\nRepresents warrants that were issued to the placement agent as compensation for its role in the Company’s public offering of ordinary shares in June 2025.\nRepresents amounts due to Oramed Pharmaceuticals Inc. as of December 31, 2025. Oramed became a related party upon completion of the March 2026 transaction.\nIncludes balances attributable to Oramed Pharmaceuticals Inc., a related party, of $6,542 as of March 31, 2026.\nIncludes balances attributable to Oramed Pharmaceuticals Inc., a related party, of $6,557 as of March 31, 2026.\nLong-lived assets are comprised of property and equipment, net, and operating lease right-of-use assets.\n\n0001607962\n2026-03-31\n\n0001607962\n2025-12-31\n\n0001607962\n2026-01-01\n2026-03-31\n\n0001607962lfwd:CustomerAMemberus-gaap:AccountsReceivableMemberus-gaap:CreditConcentrationRiskMember\n2026-01-01\n2026-03-31\n\n0001607962lfwd:CustomerAMemberus-gaap:AccountsReceivableMemberus-gaap:CreditConcentrationRiskMember\n2025-01-01\n2025-03-31\n\n0001607962us-gaap:FairValueMeasurementsRecurringMember\n2026-03-31\n\n0001607962us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember\n2025-12-31\n\n0001607962us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember\n2026-01-01\n2026-03-31\n\n0001607962us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember\n2026-03-31\n\n0001607962us-gaap:ProductMember\n2025-01-01\n2025-03-31\n\n0001607962us-gaap:ProductMember\n2026-01-01\n2026-03-31\n\n0001607962lfwd:LeaseMember\n2025-01-01\n2025-03-31\n\n0001607962lfwd:LeaseMember\n2026-01-01\n2026-03-31\n\n0001607962lfwd:ServiceAndWarrantyMember\n2025-01-01\n2025-03-31\n\n0001607962lfwd:ServiceAndWarrantyMember\n2026-01-01\n2026-03-31\n\n0001607962\n2025-01-01\n2025-03-31\n\n0001607962lfwd:SCIProductsMembersrt:MinimumMember\n2026-03-31\n\n0001607962lfwd:SCIProductsMembersrt:MaximumMember\n2026-03-31\n\n0001607962us-gaap:FairValueMeasurementsRecurringMember\n2025-12-31\n\n0001607962us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember\n2026-03-31\n\n0001607962us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember\n2025-12-31\n\n0001607962us-gaap:MeasurementInputSharePriceMember\n2026-03-31\n\n0001607962us-gaap:MeasurementInputSharePriceMember\n2025-12-31\n\n0001607962us-gaap:MeasurementInputExpectedTermMember\n2026-03-31\n\n0001607962us-gaap:MeasurementInputExpectedTermMember\n2025-12-31\n\n0001607962us-gaap:MeasurementInputPriceVolatilityMember\n2026-03-31\n\n0001607962srt:MinimumMemberus-gaap:MeasurementInputPriceVolatilityMember\n2025-12-31\n\n0001607962srt:MaximumMemberus-gaap:MeasurementInputPriceVolatilityMember\n2025-12-31\n\n0001607962srt:MinimumMemberus-gaap:MeasurementInputRiskFreeInterestRateMember\n2025-12-31\n\n0001607962us-gaap:MeasurementInputRiskFreeInterestRateMember\n2026-03-31\n\n0001607962srt:MaximumMemberus-gaap:MeasurementInputRiskFreeInterestRateMember\n2025-12-31\n\n0001607962us-gaap:MeasurementInputExpectedDividendRateMember\n2026-03-31\n\n0001607962us-gaap:MeasurementInputExpectedDividendRateMember\n2025-12-31\n\n0001607962us-gaap:MeasurementInputPriceVolatilityMember\n2025-12-31\n\n0001607962us-gaap:MeasurementInputRiskFreeInterestRateMember\n2025-12-31\n\n0001607962lfwd:PreFundedWarrantAndWarrantLiabilitiesMember\n2025-12-31\n\n0001607962lfwd:PreFundedWarrantAndWarrantLiabilitiesMember\n2026-01-01\n2026-03-31\n\n0001607962lfwd:PreFundedWarrantAndWarrantLiabilitiesMember\n2026-03-31\n\n0001607962us-gaap:WarrantMemberlfwd:OramedPharmaceuticalsIncMember\n2026-03-31\n\n0001607962lfwd:OramedPharmaceuticalsIncMember\n2026-03-31\n\n0001607962lfwd:PrefundedWarrantsFreestandingWarrantsMemberlfwd:OramedPharmaceuticalsIncMember\n2026-03-31\n\n0001607962lfwd:OramedPharmaceuticalsIncMember\n2026-01-01\n2026-03-31\n\n0001607962\n2026-05-18\n\n0001607962lfwd:IsraelInnovationAuthorityMember\n2026-03-31\n\n0001607962lfwd:LlAndLgMember\n2026-01-01\n2026-03-31\n\n0001607962lfwd:LlAndLgMember\n2026-03-31\n\n0001607962lfwd:IsraelInnovationAuthorityMember\n2026-01-01\n2026-03-31\n\n0001607962lfwd:IsraelInnovationAuthorityMemberus-gaap:ConvertiblePreferredStockMember\n2026-01-01\n2026-03-31\n\n0001607962lfwd:IsraelInnovationAuthorityMemberus-gaap:ConvertiblePreferredStockMember\n2026-03-31\n\n0001607962us-gaap:IPOMember\n2026-01-01\n2026-03-31\n\n0001607962lfwd:DebtHostMember\n2026-03-31\n\n0001607962us-gaap:WarrantMember\n2026-03-31\n\n0001607962lfwd:EmbeddedDerivativeMember\n2026-03-31\n\n0001607962lfwd:ConvertibleNewNoteMember\n2026-01-01\n2026-03-31\n\n0001607962lfwd:OriginalSecuredNoteMember\n2025-11-14\n\n0001607962lfwd:AdditionalSecuredNotesMember\n2026-03-31\n\n0001607962lfwd:ConvertibleNewNoteMemberlfwd:OramedAndCreativeValueCapitalMember\n2026-03-25\n\n0001607962lfwd:AdditionalSecuredNotesMember\n2026-03-01\n2026-03-31\n\n0001607962lfwd:FreestandingWarrantsMemberlfwd:ConvertibleNewNoteMemberlfwd:OramedAndCreativeValueCapitalMember\n2026-03-25\n\n0001607962lfwd:ConvertibleNewNoteMemberlfwd:OramedAndCreativeValueCapitalMember\n2026-03-01\n2026-03-25\n\n0001607962\n2025-01-01\n2025-12-31\n\n0001607962lfwd:SkelableLtdMemberus-gaap:IntellectualPropertyMemberus-gaap:SubsequentEventMember\n2026-05-01\n2026-05-18\n\n0001607962lfwd:SharePurchaseAgreementMemberlfwd:AssetAcquisitionOfOratechPharmaceuticalsLtdMember\n2026-03-01\n2026-03-25\n\n0001607962lfwd:SharePurchaseAgreementMemberlfwd:AssetAcquisitionOfOratechPharmaceuticalsLtdMember\n2026-03-01\n2026-03-25\n\n0001607962lfwd:SharePurchaseAgreementMemberlfwd:AssetAcquisitionOfOratechPharmaceuticalsLtdMemberus-gaap:WarrantMember\n2026-03-25\n\n0001607962lfwd:SharePurchaseAgreementMemberlfwd:AssetAcquisitionOfOratechPharmaceuticalsLtdMemberus-gaap:WarrantMember\n2026-03-01\n2026-03-25\n\n0001607962\n2024-12-31\n\n0001607962\n2025-03-31\n\n0001607962lfwd:RegisteredDirectMember\n2026-01-01\n2026-03-31\n\n0001607962us-gaap:CommonStockMember\n2024-12-31\n\n0001607962us-gaap:AdditionalPaidInCapitalMember\n2024-12-31\n\n0001607962us-gaap:RetainedEarningsMember\n2024-12-31\n\n0001607962us-gaap:AdditionalPaidInCapitalMember\n2025-01-01\n2025-03-31\n\n0001607962us-gaap:CommonStockMember\n2025-01-01\n2025-03-31\n\n0001607962us-gaap:RetainedEarningsMember\n2025-01-01\n2025-03-31\n\n0001607962us-gaap:CommonStockMember\n2025-03-31\n\n0001607962us-gaap:RetainedEarningsMember\n2026-01-01\n2026-03-31\n\n0001607962us-gaap:RetainedEarningsMember\n2026-03-31\n\n0001607962us-gaap:AdditionalPaidInCapitalMember\n2026-03-31\n\n0001607962us-gaap:CommonStockMember\n2026-03-31\n\n0001607962us-gaap:TreasuryStockPreferredMember\n2026-03-31\n\n0001607962us-gaap:TreasuryStockPreferredMember\n2024-12-31\n\n0001607962us-gaap:TreasuryStockPreferredMember\n2025-01-01\n2025-03-31\n\n0001607962us-gaap:AdditionalPaidInCapitalMember\n2026-01-01\n2026-03-31\n\n0001607962us-gaap:CommonStockMember\n2026-01-01\n2026-03-31\n\n0001607962us-gaap:TreasuryStockPreferredMember\n2026-01-01\n2026-03-31\n\n0001607962us-gaap:RetainedEarningsMember\n2025-03-31\n\n0001607962us-gaap:TreasuryStockPreferredMember\n2025-03-31\n\n0001607962us-gaap:AdditionalPaidInCapitalMember\n2025-03-31\n\n0001607962us-gaap:RetainedEarningsMember\n2025-12-31\n\n0001607962us-gaap:TreasuryStockPreferredMember\n2025-12-31\n\n0001607962us-gaap:AdditionalPaidInCapitalMember\n2025-12-31\n\n0001607962us-gaap:CommonStockMember\n2025-12-31\n\n0001607962lfwd:EmployeeStockOptionAndRestrictedStockUnitsRsuMember\n2025-12-31\n\n0001607962lfwd:EmployeeStockOptionAndRestrictedStockUnitsRsuMember\n2026-01-01\n2026-03-31\n\n0001607962lfwd:EmployeeStockOptionAndRestrictedStockUnitsRsuMember\n2026-03-31\n\n0001607962us-gaap:EmployeeStockOptionMemberlfwd:ExercisePriceRangeTwoMember\n2026-03-31\n\n0001607962us-gaap:EmployeeStockOptionMemberlfwd:ExercisePriceRangeTwoMember\n2026-01-01\n2026-03-31\n\n0001607962us-gaap:EmployeeStockOptionMemberlfwd:ExercisePriceRangeThreeMember\n2026-03-31\n\n0001607962us-gaap:EmployeeStockOptionMemberlfwd:ExercisePriceRangeThreeMember\n2026-01-01\n2026-03-31\n\n0001607962us-gaap:EmployeeStockOptionMemberlfwd:ExercisePriceRangeFourMember\n2026-03-31\n\n0001607962us-gaap:EmployeeStockOptionMemberlfwd:ExercisePriceRangeFiveMember\n2026-01-01\n2026-03-31\n\n0001607962us-gaap:EmployeeStockOptionMemberlfwd:ExercisePriceRangeFiveMember\n2026-03-31\n\n0001607962us-gaap:EmployeeStockOptionMember\n2026-01-01\n2026-03-31\n\n0001607962us-gaap:EmployeeStockOptionMember\n2026-03-31\n\n0001607962us-gaap:EmployeeStockOptionMemberlfwd:ExercisePriceRangeMember\n2026-03-31\n\n0001607962us-gaap:EmployeeStockOptionMemberlfwd:ExercisePriceRangeFourMember\n2026-01-01\n2026-03-31\n\n0001607962srt:MinimumMemberus-gaap:EmployeeStockOptionMemberlfwd:ExercisePriceRangeFiveMember\n2026-01-01\n2026-03-31\n\n0001607962srt:MaximumMemberus-gaap:EmployeeStockOptionMemberlfwd:ExercisePriceRangeFiveMember\n2026-01-01\n2026-03-31\n\n0001607962lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnDecemberEightTwoThousandTwentyMember\n2026-03-31\n\n0001607962lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnDecemberEightTwoThousandTwentyMemberOneMember\n2026-03-31\n\n0001607962lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnDecemberEightTwoThousandTwentyMember\n2026-01-01\n2026-03-31\n\n0001607962lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnFebruaryTwentySixTwoThousandTwentyOneMember\n2026-03-31\n\n0001607962lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnDecemberEightTwoThousandTwentyMemberOneMember\n2026-01-01\n2026-03-31\n\n0001607962lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnFebruaryTwentySixTwoThousandTwentyOneOneMember\n2026-03-31\n\n0001607962lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnSeptemberTwentyNineTwoThousandTwentyOneMember\n2026-03-31\n\n0001607962lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnSeptemberTwentyNineTwoThousandTwentyOneOneMember\n2026-03-31\n\n0001607962lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnJanuaryEightTwoThousandTwentyFiveMember\n2026-03-31\n\n0001607962lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnJanuaryEightTwoThousandTwentyFiveOneMember\n2026-03-31\n\n0001607962lfwd:CertainInstitutionalPurchasersMemberlfwd:RegisteredDirectOfferingOfOrdinarySharesJulyTwoZeroTwoZeroMember\n2026-03-31\n\n0001607962lfwd:CertainInstitutionalPurchasersMemberlfwd:RegisteredDirectOfferingOfOrdinarySharesJulyTwoZeroTwoZeroMember\n2026-01-01\n2026-03-31\n\n0001607962lfwd:CertainInstitutionalPurchasersMemberlfwd:OfferingOfOrdinarySharesDecemberTwoZeroTwoZeroMember\n2026-03-31\n\n0001607962lfwd:CertainInstitutionalPurchasersMemberlfwd:OfferingOfOrdinarySharesDecemberTwoZeroTwoZeroMember\n2026-01-01\n2026-03-31\n\n0001607962\n2026-01-01\n2026-01-06\n\n0001607962\n2026-01-01\n2026-01-30\n\n0001607962lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnJanuaryEightTwoThousandTwentyFiveMember\n2026-01-01\n2026-03-31\n\n0001607962lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnJanuaryEightTwoThousandTwentyFiveOneMember\n2026-01-01\n2026-03-31\n\n0001607962lfwd:PurchaseAgreementWithCertainInstitutionalInvestorsMember\n2025-01-01\n2025-01-07\n\n0001607962lfwd:PurchaseAgreementForIssuanceAndSaleOfOrdinarySharesAndOrdinaryWarrantsMember\n2025-01-07\n\n0001607962lfwd:PurchaseAgreementWithCertainInstitutionalInvestorsMember\n2025-01-07\n\n0001607962lfwd:HCWainwrightAndCoLlcMemberlfwd:PurchaseAgreementWithCertainInstitutionalInvestorsMember\n2025-01-07\n\n0001607962us-gaap:CostOfSalesMember\n2025-01-01\n2025-03-31\n\n0001607962us-gaap:CostOfSalesMember\n2026-01-01\n2026-03-31\n\n0001607962us-gaap:ResearchAndDevelopmentExpenseMember\n2025-01-01\n2025-03-31\n\n0001607962us-gaap:ResearchAndDevelopmentExpenseMember\n2026-01-01\n2026-03-31\n\n0001607962us-gaap:SellingAndMarketingExpenseMember\n2025-01-01\n2025-03-31\n\n0001607962us-gaap:SellingAndMarketingExpenseMember\n2026-01-01\n2026-03-31\n\n0001607962us-gaap:GeneralAndAdministrativeExpenseMember\n2025-01-01\n2025-03-31\n\n0001607962us-gaap:GeneralAndAdministrativeExpenseMember\n2026-01-01\n2026-03-31\n\n0001607962lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnJuneTwentySixTwoThousandTwentyFiveMember\n2026-03-31\n\n0001607962lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnJuneTwentySixTwoThousandTwentyFiveOneMember\n2026-03-31\n\n0001607962lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnJuneTwentySixTwoThousandTwentyFiveMember\n2026-01-01\n2026-03-31\n\n0001607962lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnJuneTwentySixTwoThousandTwentyFiveOneMember\n2026-01-01\n2026-03-31\n\n0001607962us-gaap:EmployeeStockOptionMemberlfwd:ExercisePriceRangeOneMember\n2026-03-31\n\n0001607962us-gaap:EmployeeStockOptionMemberlfwd:ExercisePriceRangeOneMember\n2026-01-01\n2026-03-31\n\n0001607962lfwd:IncentiveCompensationPlan2025Membersrt:AffiliatedEntityMember\n2025-03-31\n\n0001607962lfwd:EmployeeStockOptionAndRestrictedStockUnitsRsuMember\n2025-01-01\n2025-03-31\n\n0001607962\n2026-02-01\n2026-02-24\n\n0001607962\n2026-02-23\n\n0001607962\n2026-02-24\n\n0001607962lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnFebruaryTwentySixTwoThousandTwentyOneMember\n2026-01-01\n2026-03-31\n\n0001607962lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnFebruaryTwentySixTwoThousandTwentyOneOneMember\n2026-01-01\n2026-03-31\n\n0001607962lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnSeptemberTwentyNineTwoThousandTwentyOneMember\n2026-01-01\n2026-03-31\n\n0001607962lfwd:WarrantsToPurchaseOrdinarySharesIssuedOnSeptemberTwentyNineTwoThousandTwentyOneOneMember\n2026-01-01\n2026-03-31\n\n0001607962lfwd:IncentiveCompensationPlan2025Membersrt:AffiliatedEntityMember\n2025-12-31\n\n0001607962us-gaap:ConvertibleNotesPayableMember\n2026-03-31\n\n0001607962country:IL\n2026-03-31\n\n0001607962country:IL\n2025-12-31\n\n0001607962country:US\n2026-03-31\n\n0001607962country:US\n2025-12-31\n\n0001607962country:DE\n2026-03-31\n\n0001607962country:DE\n2025-12-31\n\n0001607962lfwd:CustomerAMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember\n2026-01-01\n2026-03-31\n\n0001607962lfwd:CustomerAMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember\n2025-01-01\n2025-03-31\n\n0001607962country:US\n2025-01-01\n2025-03-31\n\n0001607962country:US\n2026-01-01\n2026-03-31\n\n0001607962country:DE\n2025-01-01\n2025-03-31\n\n0001607962country:DE\n2026-01-01\n2026-03-31\n\n0001607962srt:AsiaPacificMember\n2025-01-01\n2025-03-31\n\n0001607962srt:AsiaPacificMember\n2026-01-01\n2026-03-31\n\n0001607962lfwd:RestOfWorldMember\n2025-01-01\n2025-03-31\n\n0001607962lfwd:RestOfWorldMember\n2026-01-01\n2026-03-31\n\n0001607962srt:EuropeMember\n2025-01-01\n2025-03-31\n\n0001607962srt:EuropeMember\n2026-01-01\n2026-03-31\nlfwd:Percent\nlfwd:Share\niso4217:USD\niso4217:USDxbrli:shares\nlfwd:Year\nxbrli:pure\nxbrli:shares\n\n \n\n \n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\nWashington, D.C. 20549\n\n \n\n**FORM 10-Q**\n\n \n\n☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n\n \n\nFor the quarterly period ended March 31, 2026\n\n \n\n☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n** **\n\nFor the transition period from             to            \n\n \n\nCommission File Number: 001-36612\n\n \n\n \n\n**Lifeward Ltd.**\n\n(Exact name of registrant as specified in charter)\n\n \n\nIsrael\n \nNot applicable\n\n(State or other jurisdiction of incorporation or organization)\n \n(I.R.S. Employer Identification No.)\n\n \n\n2 Cabot Rd., Hudson, MA\n \n01749\n\n(Address of principal executive offices)\n \n(Zip Code)\n\n \n\n+508.251.1154\n\nRegistrant's telephone number, including area code\n\n \n\nNot Applicable\n\n(Former name, former address and former fiscal year, if changed since last report)\n\nSecurities registered pursuant to Section 12(b) of the Act\n\n \n\n**Title of each class**\n**Trading Symbol**\n**Name of each exchange on which registered**\n\nOrdinary shares, no par value\nLFWD\nNasdaq Capital Market\n\n \n\nIndicate by a check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.\n\n \n\nYes ☒ No ☐\n\n \n\nIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).\n\n \n\nYes ☒ No ☐\n\n \n\nIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.\n\n \n\n \n\nLarge accelerated filer ☐\nAccelerated filer ☐\n\nNon-accelerated filer ☒\nSmaller reporting company ☒\n\n \nEmerging growth company ☐\n\n \n\n \n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\n \n\nIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).\n\n \n\nYes ☐ No ☒\n\n \n\nAs of May 18, 2026, the registrant had outstanding 2,814,409 ordinary shares.\n\n \n\n \n\n**LIFEWARD LTD.**\n\n \n\n**FORM 10-Q**\n\n**FOR THE QUARTER ENDED MARCH 31, 2026**\n\n \n\n**TABLE OF CONTENTS**\n\n \n\n Page No.\n\n[GENERAL AND WHERE YOU CAN FIND MORE INFORMATION](#a_moreinfo)ii\n\n**PART I ****FINANCIAL INFORMATION**F - 1\n\n[ITEM 1.](#a_item1) [FINANCIAL STATEMENTS](#a_item1)F - 1\n\n [CONDENSED CONSOLIDATED BALANCE SHEETS - MARCH 31, 2026 (unaudited) AND DECEMBER 31, 2025](#a_CONDENSEDCONSOLIDATEDBALANCESHEETS)F - 1\n\n [CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS – THREE MONTHS ENDED MARCH 31, 2026 AND 2025 (unaudited)](#ope)F - 3\n\n [CONDENSED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY – MARCH 31, 2026 AND 2025 (unaudited)](#a_CONDENSEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY)F - 4\n\n [CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS – THREE MONTHS ENDED MARCH 31, 2026 AND 2025 (unaudited)](#a_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS)F - 5\n\n [NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)](#notes)F - 6\n\n[ITEM 2.](#a_Item2) [MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS](#a_Item2)1\n\n[ITEM 3.](#a_Item3) [QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK](#a_Item3)9\n\n[ITEM 4.](#a_Item4) [CONTROLS AND PROCEDURES](#a_Item4)9\n\n**PART II ****OTHER INFORMATION**10\n\n[ITEM 1.](#part2_item1) [LEGAL PROCEEDINGS](#part2_item1)10\n\n[ITEM 1A.](#part2_item1a) [RISK FACTORS](#part2_item1a)10\n\n[ITEM 2.](#part2_item2) [UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS](#part2_item2)10\n\n[ITEM 3.](#part2_item3) [DEFAULTS UPON SENIOR SECURITIES](#part2_item3)10\n\n[ITEM 4.](#part2_item4) [MINE SAFETY DISCLOSURES](#part2_item4)10\n\n[ITEM 5.](#part2_item5) [OTHER INFORMATION](#part2_item5)10\n\n[ITEM 6.](#part2_item6) [EXHIBITS](#part2_item6)11\n\n**SIGNATURES** 12\n\ni \n\n \n\n**Introduction and Where You Can Find Other Information**\n\n \n\nAs used in this quarterly report on Form 10-Q (this “quarterly report”), the terms “Lifeward,” the “Company,” “LL,” “we,” “us” and “our” refer to Lifeward Ltd. and its subsidiaries, unless the context clearly indicates otherwise. Our website is www.golifeward.com. Information contained in, or that can be accessed through, our website does not constitute a part of this quarterly report and is not incorporated by reference herein. We have included our website address in this quarterly report solely for informational purposes. Information that we furnish to or file with the Securities and Exchange Commission (the “SEC”), including annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and any amendments to, or exhibits included in, these reports are available for download, free of charge, on our website as soon as reasonably practicable after such materials are filed with or furnished to the SEC. Our SEC filings, including exhibits filed or furnished therewith, are also available on the SEC’s website at http://www.sec.gov.\n\n \n\nSpecial Note Regarding Forward-Looking Statements   \n\n \n\nIn addition to historical information, this quarterly report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, that are based on our management’s beliefs and assumptions and on information currently available to our management. Forward- looking statements include information concerning our possible or assumed future results of operations, business strategies, financing plans, competitive position, industry environment, potential growth opportunities, potential market opportunities and the effects of competition. Forward-looking statements may include projections regarding our future performance and, in some cases, can be identified by words like “anticipate,” “assume,” “believe,” “could,” “seek,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “future,” “should,” “will,” “would” or similar expressions that convey uncertainty of future events or outcomes and the negatives of those terms. These statements may be found in the section of this quarterly report titled “Part I, Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in this quarterly report. These statements include, but are not limited to, statements regarding:\n\n \n\n•our expectations regarding future growth, including our ability to increase sales in our existing geographic markets and expand to new markets;\n\n \n\n•our ability to continue as a going concern for the next twelve months;\n\n \n\n•our ability to maintain and grow our reputation and the market acceptance of our products;\n\n \n\n•our ability to achieve reimbursement from third-party payors for Private, Governments, and Medicare & Medicaid Services (“CMS”) coverage for our products, including our ability to successfully submit and gain approval of cases for Medicare coverage through Medicare Administrative Contractors (“MACs”);\n\n \n\n •our ability to successfully integrate Oratech Pharmaceuticals Ltd . into our organization, and realize the anticipated benefits therefrom;\n\n \n\n •the expected timing and results of the ORMD-0801 clinical trial;\n\n \n\n•our ability to have sufficient funds to meet certain future capital requirements, which could impair our efforts to develop and commercialize existing and new products;\n\n \n\n•our ability to achieve expected operating efficiencies and sustain or improve operating expense reductions, and our ability to handle any business disruptions that may occur in connection with streamlining operations;\n\n \n\n•our reliance on third-party contract manufacturers for the production of our AlterG Anti-Gravity Systems and our ability to maintain product quality, ensure timely production and delivery, and manage potential supply chain disruptions;\n\n \n\n•our ability to leverage our sales, marketing and training infrastructure;\n\n \n\n•our ability to grow our business through acquisitions of businesses, products or technologies, and the failure to manage acquisitions, or the failure to integrate them with our existing business;\n\n \n\n•our ability to obtain certain components of our products from third-party suppliers and our continued access to our product manufacturers;\n\n \n\n•our ability to improve our products and develop new products;\n\n \n\n•our compliance with medical device reporting regulations to report adverse events involving our products, which could result in voluntary corrective actions or enforcement actions such as mandatory recalls, and the potential impact of such adverse events on our ability to market and sell our products;\n\n \n\n•our ability to gain and maintain regulatory approvals and to comply with any post-marketing requests;\n\n \n\n•the risk of a cybersecurity attack or incident relating to our information technology systems significantly disrupting our business operations;\n\n \n\n•our ability to maintain adequate protection of our intellectual property and to avoid violation of the intellectual property rights of others;\n\n \n\n•the impact of substantial sales of our shares by certain shareholders on the market price of our ordinary shares;\n\n \n\n•our ability to maintain compliance with the continued listing requirements of the Nasdaq Capital Market and the risk that our ordinary shares will be delisted if we cannot do so;\n\n \n\n•our ability to effectively use the proceeds from our recent offerings of securities;\n\n \n\n•our ability to repay amounts due, and perform our obligations under and comply with the terms and conditions of, our Secured Promissory Notes;\n\n \n\n•the impact of the market price of our ordinary shares on the determination of whether we are a passive foreign investment company;\n\n \n\n•market and other conditions, including the extent to which inflationary pressures, interest rate and currency rate fluctuations, and changes in trade policies (including tariffs and trade protection measures that have been or may in the future be imposed by the U.S. or other countries), or global instability may disrupt our business operations or our financial condition or the financial condition of our customers and suppliers, including the ongoing Russia-Ukraine conflict, ongoing conflict in the Middle East (including any escalation or expansion) and the increasing tensions between China and Taiwan; and\n\n \n\n•other factors discussed in the “Risk Factors” section of our 2025 annual report on Form 10-K and in our subsequent reports filed with the SEC.\n\n \n\nThe preceding list is not intended to be an exhaustive list of all forward-looking statements contained in this quarterly report. The statements are based on our beliefs, assumptions, and expectations of future performance, taking into account the information currently available to us. These statements are only predictions based upon our current expectations and projections about future events. There are important factors that could cause our actual results, levels of activity, performance, or achievements to differ materially from the results, levels of activity, performance or achievements expressed or implied by the statements. In particular, you should consider the risks provided under “Part I, Item 1A. Risk Factors” of our 2025 annual report on Form 10-K, and in other reports subsequently filed by us with, or furnished to, the SEC.\n\n \n\nYou should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or will occur.\n\n \n\nAny forward-looking statement in this quarterly report speaks only as of the date hereof. Except as required by law, we undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future developments or otherwise.\n\nii \n\n \n\n**PART I - FINANCIAL INFORMATION**"}